AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 41 min read$UTHR

United Therapeutics Corporation (UTHR) Q3 Revenue Rises 4% to $832.5M

United Therapeutics reported Q3 2026 revenue of $832.5M, up 4% YoY from $799.5M. The company authorized a $2.0B share repurchase program through October 2027.

Original reporting
tradingview.com
Published Nov 4, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
United Therapeutics Corporation (UTHR) Q3 Revenue Rises 4% to $832.5M — source image
Source · tradingview.com
Decision brief

The 30-second read

$UTHRBearishMed
01

Why it matters

The earnings beat and buyback could attract short-term buying, but investors should monitor guidance and pipeline developments.

02

Market read

First earnings release for the quarter provides fresh data that can move the stock in early trading.

03

What to watch

Potential regulatory or pipeline risks not discussed in the brief release.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

United Therapeutics released its Q3 2026 operating update, highlighting modest revenue growth and a new share repurchase program.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

Q3 2026 revenue rose 4% YoY to $832.5M and a $2.0B share repurchase program was approved.

Expected impact

potential upside as investors price in earnings beat and buyback authorization

Evidence & confidence

First report of earnings with better-than-expected revenue and a sizable repurchase program typically drives buying pressure.

Market effects

Sector

Positive for biotech and specialty pharma peers as earnings beat may lift sector sentiment.

Regional

U.S. biotech stocks could see modest gains in early trading.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

Buyback may be a defensive move; revenue growth is modest and could be offset by higher expenses.

Key entities

  • company
    United Therapeutics Corporation

    U.S.-listed biotech firm reporting Q3 results.

Read at source← All news

StoryUnited Therapeutics reports Q3 2026 earnings miss despite revenue beat

Also covered by

2 outlets

Related articles

NOV 4
$UTHRMed

United Therapeutics Q3 2026 slides: record revenue, robust pipeline

United Therapeutics (UTHR) reported Q3 2026 revenue of $833M, up 4% YoY, but missed EPS estimates, causing a 2.75% stock decline. Tyvaso franchise revenue grew 5% YoY to $504M. The company advanced its pipeline, with FDA accepting applications for Tyvaso in IPF and ralinepag in PAH, both with 2027 PDUFA dates. Operating cash flow was $1.4B, and a $2B share repurchase program was authorized.

investing.com7 min
NOV 4
$UTHRMedAI 8/10

United Therapeutics Q3 2026 Revenue Up 4%, Net Income Falls 24%

United Therapeutics (UTHR) reported Q3 2026 revenue of $832.5M, up 4% YoY, but net income fell 24% to $258.6M due to higher R&D spending and competitive pressures. EPS declined 20% to $5.71. Tyvaso DPI sales rose 13%, while nebulized Tyvaso fell 12%. R&D expenses surged 119% to $279.2M, partly due to the Thymmune acquisition. The company repurchased shares under a 10b5-1 plan and a $2B repurchase program.

minichart.com.sg2 min
NOV 4
$UTHRHigh

United Therapeutics buys out Pfizer royalty for $525 million

United Therapeutics (UTHR) will pay $525M to Pfizer's Arena subsidiary to end royalty obligations on ralinepag, a drug for pulmonary arterial hypertension. The FDA is reviewing an application for oral ralinepag, with a decision expected by June 24, 2027. United Therapeutics acquired rights to ralinepag in 2018 and is also developing an inhaled version. According to the company, the transaction reflects confidence in the drug's revenue potential.

investing.com1 min